Major findings of the clinical evidences of Cuban policosanol on stroke
| Author | Year | Study population | Dose | Major findings |
|---|---|---|---|---|
| Ortega et al. [47] | 2006 | Fifty patients who have suffered ischemic stroke | Cuban policosanol (20 mg/day) was administered during the acute phase and 5 years after the ischemic stroke | Cuban policosanol improved neurological recovery and prevented the recurrence of new vascular events. Treatment was well tolerated |
| Sánchez et al. [48] | 2010 | Fifty-five patients with previous TIA | Cuban policosanol (20 mg/day) plus aspirin (125 mg/day) during 5 years | Combination therapy improved neurological recovery and reduced recurrence of vascular events. Treatment was well tolerated |
| Sánchez et al. [49] | 2012 | Ninety-two patients who had suffered a recent moderate to severe ischemic stroke | Cuban policosanol (20 mg/day) plus aspirin (125 mg/day) compared to placebo plus aspirin 125 mg/day during 24 weeks | Combination therapy significantly improved the neurological score and reduced platelet aggregation with more efficacy than aspirin monotherapy. Unlike aspirin the combination produced antioxidant effect. Treatments were well tolerated |
| Sánchez et al. [52] | 2016 | Sixty patients that recently suffered an ischemic stroke 30 days after stroke onset | Cuban policosanol (20 mg/day) plus aspirin (125 mg/day) and atorvastatin (20 mg/day) plus aspirin (125 mg/day) for 12 weeks | Both combinations therapies improved similarly neurological recovery and prevented recurrent cerebrovascular events. Both combinations reduced cholesterol, with atorvastatin being more effective, unlike which policosanol increased HDL-C |